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Dendritic cells (DCs), the most important professional antigen-presenting cells (APC), play crucial role in both immunity and
tolerance. It is well known that DCs are able to mount immune responses against foreign antigens and simultaneously tolerate self-
antigens. Since DCs can be modulated depending on the surrounding microenvironment, they can act as a bridge between innate
and adaptive immunity. However, the mechanisms that support this dual role are not entirely clear. Recent studies have shown
that DCs can be manipulated ex vivo in order to trigger their tolerogenic profile, what can be a tool to be used in clinical trials
aiming the treatment of various diseases and the prevention of transplant rejection. In this sense, the blockage of costimulatory
molecules on DC, in the attempt of inhibiting the second signal in the immunological synapse, can be considered as one of the
main strategies under development. This review brings an update on current therapies using tolerogenic dendritic cells modulated
with costimulatory blockers with the aim of reducing transplant rejection. However, although there are current clinical trials
using tolerogenic DC to treat allograft rejection, the actual challenge is to modulate these cells in order to maintain a permanent
tolerogenic profile.
1. Background
The main goal of a successful transplant is to promote
immune tolerance of the transplanted organ or tissue, allow-
ing the reestablishment of normal physiological functions,
without generating damage to the recipient or to the trans-
planted tissue. The concept of tolerance in transplantation
is understood as a state in which no pathological immune
response is generated against the transplanted organ or tissue.
This condition would make the graft viable while retaining
the necessary immune responses against other unknown
antigens [1, 2]. Thereby, the relationship between tolerance
and immunity must be well balanced, since any alteration in
one of the parts can cause pathophysiological modifications
and, consequently, can trigger changes in the immune system
that can ultimately lead to autoimmunity or graft rejection
[3]. In this context, it is known that a successful transplant
relies on a deep understanding of the immune system allied
with the balance and maintenance of effector and regulatory
immune mechanisms [1, 4].
However, even successful transplants can have severe
long-term complications, which can culminate in allograft
rejection. Several immunossupressor treatments have been
developed in order to reduce transplant rejection. However,
despite significant advances on immunosuppressive strate-
gies, antirejection drugs still present serious side effects,
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Figure 1: Schematic representation of the DC and T cell interaction: the main costimulatory molecules. Activation of T cell involves both
interactions between the T cell costimulatory receptors, CD28 with their cognate ligands, CD80, and CD86 (B7 family) as well as the
CD40L/CD40 pathway. Other costimulatory molecules, such as OX40/OX40-L and TIM-1 and PD-1/PD-L1, were not represented here. DC:
dendritic cell; MHC II: major histocompatibility complex II; TCR: T cell receptor; CD40L: CD40 ligand.
such as high susceptibility of opportunistic infectious dis-
eases, or even inefficient suppression of immune responses
against the allograft. The knowledge acquisition about the
immune regulation mechanisms, especially about the role
of the antigen-presenting cells (APC) in tolerance, can help
researchers propose new strategies and immunotherapies to
prevent rejection [5].
Among the APC, dendritic cells (DCs) represent the
first line of immune cell defense against pathogens and
constitute a bridge between innate and adaptive immune
response. As represented in Figure 1, DCs are the most
important APC for naive T cells [5–8] and can exert either
immunogenic or tolerogenic functions. Depending on the
received signals, these cells can become tolerogenic, that
is, can inhibit antigen-specific immune response [7, 9–13].
When TCR interacts with the peptide-MHC (pMHC) on
the surface of the APC (first signal) and it is not followed
by the interaction between costimulatory molecules (second
signal), it can induce anergy on T cells [14]. Dendritic cells
express important costimulators to T cell activation, such
as the B7 family molecules: CD80 (B7-1) and CD86 (B7-2),
playing an important role in either tolerogenic or immuno-
genic responses. Therefore, the handling of costimulatory
molecules, aiming the application of DC for therapeutic
purposes in immune disorders such as allergies and autoim-
munities, as well as in vaccination and transplantation, has
received extensive attention [15].
In this sense, in the attempt of modulating the activity
of DC on the treatment of autoimmunity, hypersensibility,
and transplant rejection, many researchers aim to develop
therapies based on tolerogenic DC (tol-DC). Previous data
has shown that DC modulated by interleukin- (IL-) 10 or
transforming growth factor-beta (TGF-𝛽) became refractory
to sustain the in vitro proliferation of antigen-specific effector
T lymphocytes [12, 13]. Additionally, adoptive transfer of DC,
modulated by inhibitory cytokines such as IL-10, also leads
to a reduction of in vivo delayed-type hypersensibility (DTH)
responses [16].
Apart from DC, regulatory T (Treg) cells, particularly
CD4+ CD25+ Foxp3+ lymphocytes, play an important role in
inducing and maintaining tolerance, promoted by cell to cell
contact or by secreted cytokines such as IL-10 andTGF-𝛽 [17–
19].
In this review, we focus our attention on current knowl-
edge related to immunotherapeutic advances based on the
use of tolerogenic DC through inhibition of the second
signal, which contribute to increasing survival of transplanted
organs and tissues and reducing the use of immunosuppres-
sive drugs.
2. Innate Immune System on Graft Rejection
Even though the role of the adaptive immune system through
cellular and humoral responses in transplant rejection is well
known, many researchers have outlined the involvement of
components of the innate immune system in themechanisms
of alloreactivity and rejection. Among these components, the
most studied are the toll-like receptors (TLR), complement
system, natural killer (NK) cells, DC, granulocytes, and
inflammatory cytokines which perform different functions in
innate immune responses [20–22].
In this regard, TLR links innate and adaptive immunity
and its signaling leads to the transcription of genes involved
in inflammatory responses resulting in the production of
proinflammatory cytokines and chemokines, antimicrobial
peptides, adhesion molecules, enhanced antigen presenta-
tion, and upregulation of costimulatory molecules in APC
[20, 21]. Corroborating this fact, it was demonstrated in
mouse models of graft versus host disease (GVHD) that
elevated doses of radiation during pretransplant increase
the epithelial damage of mucosal tissues, allowing bacterial
components to pass through the barrier. These components
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activate host and/or donor APC by interacting with pattern
recognition receptors (PRR), such as TLR, converting these
APC into an activated profile that is able to prime alloreactive
donor-derived T cells, resulting in a more severe GVHD
[23].
Currently, complement activation is known to occur
in transplant rejection and contribute to progression of
rejection. Specifically, activation of the lectin pathway of the
complement system is implicated in allograft rejection. Also,
the role of complement system in modulating regulatory T
cells is under investigation [24–27]. Recent study suggests
that C3a and C5a signaling promotes cell proliferation of
activated T cells and reduces induced-Treg (iTreg) generation
and stability [28].
Macrophages were considered critical components in
both acute cellular allograft rejection and chronic injury [29].
However, it is already known that macrophages can play both
detrimental and beneficial functions in allograft rejection.
In initial stages of the transplant, the immune response can
create a proinflammatory microenvironment that favors the
differentiation of M1 macrophages (previously referred to as
classically or alternatively activated macrophages). M1 phe-
notype is a proinflammatory cell type, characterized by secre-
tion of proinflammatory cytokines, high phagocytic activity,
and production of reactive oxygen species. As inflammation
recedes, this may alter the milieu to favor M2 differentiation.
M2 macrophages have an immunomodulatory role, since
they produce IL-10, presenting reduced phagocytic activity
and increased arginase production [30].
This hypothesis was supported by an assay with CCR5−/−
mice that exhibited reduced macrophage accumulation after
transplantation. In this model, M2 macrophage activation
was increased while M1 macrophage activation was reduced
after transplantation, in comparison with control mice [31].
However, a recent study with human biopsies showed con-
troversial data, since a M2 macrophage infiltration was
associated with inflammation, injury, and fibrosis in renal
allograft [32, 33].
Additionally, NK cells are an important component of the
innate immune system, helping to recognize allogeneicMHC
and are capable of producing proinflammatory cytokines.
NK cells can impair tolerance induction in a solid organ
transplant and can also lead to acute and chronic rejection
of allogeneic transplant [34–36]. It happens because NK
cells can kill either directly donor cells through granzyme,
perforin, Fas ligand (FasL), and tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) pathways [37–40] or
indirectly by lysing Treg cells or by promoting CD4+ T cell
activation [36, 41, 42].
Controversially, NK and NKT cells have been known to
be enrolled on allograft tolerance induction. This role of NK
cells can be influenced by immunosuppressive therapies such
as calcineurin inhibitors or steroids [35, 43, 44].The suppres-
sive role of NK cells has been observed on the allorecognition
suppression of T cells by a perforin-dependent mechanism
[45] and also by killing the donor antigen-presenting cells
[46]. Also, NK cells can regulate macrophage activation
in transplanted tissue or organ by a mechanism partially
dependent on an activating receptor known as natural killer
group 2, member D (NKG2D) [47].
Invariant NKT (iNKT) cells have regulatory functions
on the Th1/Th2 imbalance by releasing Th2 cytokines such
as IL-4 and IL-5 that antagonize the Th1 responses related
with acute rejection [48, 49]. Also, repeated activation of
NKT cells by 𝛼-galactosylceramide leads to IL-10 production
[50, 51]. Therefore, the success of tolerance protocols in
transplantation will require the administration of agents
capable of suppressing innate immunity as well as adaptive
immunity [52].
2.1. Tolerogenic Potential of Dendritic Cells on Graft Rejection.
Dendritic cells are a potential tool for therapeutic applications
in transplantation and strategies that promote DC tolero-
genicity are under evaluation [53–56]. The discovery of DC’s
function is considered a landmark in the field of immunology,
since it plays a relevant role in the interaction between innate
and adaptive immune response. In 1973, Steinman and Cohn
characterized and named DCs, a key population in naive T
lymphocyte activation [57].These studies originated from the
necessity of a better understanding of how antigens could
activate T cells and how this activation contributed to the
effector mechanisms of the immune response. Steinman’s
studies have demonstrated that DC can be functionally char-
acterized by the presence of high levels of MHC expression.
Soon after, the importance of the DCs’ maturation stage for
their immunogenic or tolerogenic functions became clear
[58]. These APC, widely distributed in lymphoid tissues,
mucosal epithelium, and parenchymal organs [58, 59], are
originating frommyeloid or lymphoid precursors in the bone
marrow and circulate in the bloodstream as immature cells
before migrating to peripheral tissues [59]. In innate immu-
nity, these cells respond to pathogen-associated molecular
patterns (PAMPs) of microbes by generating and secreting
inflammatory cytokines. In adaptive immunity, these cells
process and present antigen to T cells that leads to their
activation [60].
In humans, two major subpopulations of DC were char-
acterized: conventional DC (cDC) and plasmacytoid DC
(pDC). When stimulated by microbial antigens via TLR-
2 and TLR-4, cDC produces large amounts of IL-12 that
drives immune response to a Th1 profile. Conventional DC
also activates cytotoxic lymphocytes (CTL) in a process
known as cross-presentation. On the other hand, pDC has
a lower capacity of antigen uptake. However, pDC expresses
intracellular TLR 7 and TLR 9, which detect ssRNA and
CpG DNA motifs, respectively. pDC’s main function is to
initiate antiviral responses producing large amounts of type
I interferons such as IFN-𝛼 and INF-𝛽. Together, cDC
and pDC can distinctively contribute to protecting the host
against pathogens [61, 62].
In an inflammatorymicroenvironment, DCs initiate their
maturation process by undergoing changes in their morphol-
ogy that facilitate the interaction with naive T cells. The
hallmark of the mature stage is the upregulation of MHC and
costimulatory molecules on DC surface. Another relevant
factor is that DCs dramatically increase their migratory
capacity due to the augmentation in chemokines expression, a
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process that occurs by the upregulation of the CCR7 receptor
and their interaction with twomajor chemokines, CCL19 and
CCL21. Naive T cells also express CCR7 and, as DC, migrate
to the lymph node regions, thus increasing the likelihood of
interacting between APC and naive T lymphocyte [63]. The
matured and activated DCs cease to recognize and process
antigens, consequently preventing the presentation of self-
antigens at the site of inflammation. In summary, the set of
events that occur during maturation can mold DCs as highly
effective inducers of proliferation and differentiation of naive
T cells [63].
After exposure to antigen and crosstalk with T cells,
DCs express high levels of costimulatory molecules and
cytokines. In this regard, tolerogenic- (tol-) DC can be
generated by altering these signals [64–66]. In order to
achieve a tolerogenic profile, a DC must be immature, which
means that the maturation degree of a DC can determine
its tolerogenic capacity. According to this, the immature
DC expresses low levels of MHC class II and low levels of
costimulatory molecules, such as CD40, CD80, and CD86,
and, consequently, it presents a low capacity of activating
T cells, which is potentially associated with T cell anergy
and increased Tregs generation. In this context, immature
DC has demonstrated its ability of negatively regulating
immunogenic responses to alloantigen in animal models [67,
68].
It is well known that immature cDC generated in vitro
from bone marrow cells in the presence of the granulocyte-
macrophage-colony stimulating factor (GM-CSF) adminis-
tered seven days before the heterotopic cardiac transplanta-
tion graft in rats produces a significant increase in survival
time of the graft.This primarily occurs because the immature
DCpresents a reduced expression of costimulatorymolecules
[69].
Regarding the secretion of cytokines, immature tol-DC
can also be generated in vitro in the presence of specific
cytokines. One of the major cytokines that contribute to
the generation of tol-DC is the IL-10. DC modulated by IL-
10 inhibits the expression of MHC class II and of CD80
and CD86 costimulatory molecules, acquiring the ability to
induce T cell anergy. IL-2, secreted mainly by activated T
CD4+ lymphocytes, also plays an important role inmaintain-
ing tolerance by regulatory T cells, since these cells are highly
dependent on IL-2 for their functions [59].
The literature indicates that the tolerogenic DC popula-
tions have specific markers related to their tolerogenic capac-
ity as well as high expression and activity of indoleamine 2,3-
dioxygenase (IDO), a tryptophan-catabolizing enzyme [70].
The suppressive mechanism related to IDO is associated with
massive depletion of tryptophan, serotonin, andmelatonin in
the tissue microenvironment, producing immunoregulatory
metabolites, the kynurenines [71]. Besides, other metabolites
derived from tryptophan by IDO activity can also foster
the generation of Treg cells, demonstrating the important
immunosuppressive role of IDO, either by direct suppression
of T cell activation, or expansion of Treg cells. Data shows that
IDO has a greater potential to protect the tissue from damage
than to prevent the activation of T cells [70, 72].
3. Adaptive Immunity on Graft Rejection
3.1. Cellular Basis of Allograft Rejection. Much of what is
currently known about allograft rejection is mainly related to
the understanding of the effective role of T cells in alloantigen
recognition mechanisms. However, innate-adaptive immune
crosstalk is fundamental in this process. The participation
of T cells in the recognition of alloantigen occurs through
the interaction between the receptors of T lymphocytes and
allogeneic MHC expressed on APC [73], promoting the
differentiation of naive T cells into effector T cells [74]. The
migration of naive T cells to lymphoid organs is mediated by
specific chemokines, such as intercellular adhesionmolecules
(ICAM) as well as chemokine (C-Cmotif) ligand 21 (CCL21),
which allow themigration of lymphocytes through blood ves-
sels. In lymphoid organs, naive T lymphocytes can encounter
DC bearing antigen molecules. Accordingly, the naive T cells
initiate their differentiation depending on the signal intensity
that can then become effector cells [75].
The CD4+ helper T cells promote the activation of
macrophages by the production of specific cytokines, also
assisting in the differentiation of plasmocytes and con-
sequently in the production of antibodies. The helper T
cells promote the expansion of memory CD8+ T cells after
secondary exposure to antigen [76]. Many factors, including
cytokines, influence the differentiation of naive CD4+ T cells.
The major subsets of T helper effector cells areTh1,Th2,Th9,
Th17,Th22, and follicular helper T cells [77, 78]. Among them,
Th1 cells are one of the most important populations responsi-
ble for immune response evolved with the allograft rejection,
while the role ofTh2 cells is controversial; some data support
their involvement in the activation of alloimmune responses
while other data shows their contribution as a regulatory
subset [79].
More recently, the Th17 population stands out as an
important cell group related with inflammatory conditions.
In this sense, the influence of Th17 cells in the activa-
tion of inflammatory conditions in GVHD in patients was
demonstrated. These cells migrate to GVHD target organs,
as skin and mucosa, and exert their proinflammatory effects,
stimulating theTh1 effector cells migration to these sites [80].
It has been shown that another heterogeneous subset of
Foxp3+Treg cells promotes the inhibition of the activation of
T lymphocytes, balancing the intensity of immune responses
[75, 81]. In allogenic cardiac mouse model, the adoptive
transfer of Foxp3+Treg cells induced in vitro by exposition of
na¨ıve T lymphocytes to tolerogenic DC was able to provide
long-term tolerance and allograft survival [82]. In agreement
with these findings, Hu and collaborators [83] showed that
infiltrating Foxp3+Treg cells found in kidney allografts from
mouse seem to be related with the tolerance phenomenon
whereas the depletion of these cells correlates with tolerance
abrogation and decreased graft survival. However, it has been
demonstrated that Foxp3+Treg and Th17 cells populations
have a high flexibility and lineage plasticity, being able to con-
vert from one to another by a mechanism dependent on the
retinoic acid receptor-related orphan receptor 𝛾 (ROR𝛾t) [84,
85]. Supporting this, a recent investigation in a mouse car-
diac transplantation model showed that the transference of
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mesenchymal stem cells (MSC) before heart transplantation
was able to induce Treg over Th17 development. According
to the authors, the identification of IL-17A+ Foxp3+ double-
positive and ex-IL-17-producing IL-17A-Foxp3+ T cells in
heart and spleen of the recipients argues for direct conversion
of Th17 cells into Treg cells as the underlying mechanism of
immune regulation in MSC-mediated allograft survival [85].
Among immunological molecules related to allograft
response, human leukocyte antigen (HLA)-G, a nonclassical
class of I HLA detected in the plasma, has been associated
with the reduction of acute and chronic rejection [86]. This
molecule has local immunomodulatory properties, due to its
limited polymorphism, contributing to the survival of allo-
geneic liver transplants. HLA-G1 to G4 aremembrane-bound
molecules whileHLA-G5 toG7 are solublemolecules (sHLA-
G) [87, 88]. HLA-G was previously identified as a naturally
occurring tolerance-inducing molecule. Under physiological
condition, HLA-G has a low tissue distribution, being mainly
found in medullary thymic epithelial cells, cornea, pancreas,
and mesenchymal stem cells. Their tolerogenic functions
were observed during pregnancy for preventingmaternal NK
cytotoxicity and suppressing the activation and proliferation
of CD4 and CD8 T cells [89, 90]. It is already known
that low doses of sHLA can stimulate Th2 and inhibit Th1
profile [91, 92]. However, it was also demonstrated that sHLA
induced proliferation and IFN-𝛾 production by NK cells,
contributing to vascular remodeling of spiral arteries and
allowing successful embryo implantation in pregnancymodel
[92].
3.2.Humoral Basis of AllograftRejection. Antibody-mediated
immune response, described in the literature as hypera-
cute graft rejection, occurs mainly in highly vascularized
organs transplanted into previously sensitized recipients.
This phenomenon can occur in distinct conditions: when
patients might have received multiple blood transfusions,
when they have been pregnant, or when they could possibly
have had a previous transplant treatment. All these situations
would explain why they would be carrying antibodies against
donor antigens (DSAs). The result is a hyperacute rejection
mediated by specific antibodies due to an incompatibility
between donor and recipient, manifested by a strong reaction
against the donor HLA antigens in the vascular endothelial
cells of the graft [93].
The interaction between graft endothelial cells and host
antibodies provides rapid complement activation and sub-
sequent graft loss. This is caused by a serious inflammatory
injury in the endothelium, losing its capacity of retaining
fluid within the intravascular space [94–96]. Hereupon, the
evolution of therapies for reducing the impact of B cells and
DSA is a goal on allograft survival.
4. Immunotherapies Targeting
Allograft Rejection
The establishment of an effective standard therapy for the
induction of tolerance in the prevention of graft rejection is
of great complexity. Hence, the long-term graft survival is
often dependent on the maintenance of immunosuppressive
treatment, which generates serious side effects [97, 98].
Rather, it would be interesting to have treatments withmilder
side effects such as tolerance induction therapy [4, 99],
highlighting the importance of creating protocols based on
nonaggressive immunosuppressive drugs.
In this sense, the progression of research and immuno-
logical knowledge allowed the development of new immuno-
suppressive drugs and molecules based on animal model
studies. The literature describes a wide range of tolero-
genic therapeutics, many of which are still under exper-
imental studies. However, some biological therapies have
shown considerable success in allogeneic transplant, at least
in the short term [100–102]. Thereby, therapies based on
inducing cellular tolerance have become important alter-
natives for reducing the administration of immunosup-
pressive drugs in the attempt of improving the life qual-
ity of transplanted patients [4, 99]. However, more stud-
ies are necessary to investigate the risks associated with
modern cellular therapies, since they can be related to an
increased number of malignancy and infectious diseases
[103, 104].
4.1. Immunotherapy Based on the Second Signal Blockage. As
previously mentioned, the secondary signaling has a great
importance to the T cell immune response and can be a
relevant tool to the development of immunological tolerance.
Thereby, new immunotherapies are under evaluation for
the treatment of autoimmune diseases, hypersensibility, and
transplantation. Several studies have focused on the gener-
ation of tol-DC by blocking the costimulatory pathways, as
summarized in Table 1 [5, 98, 105].
Among costimulatory molecules, T cells express the
CD28 receptor on their surface as the main responsible
molecule for binding to the B7-1 and B7-2 (CD80 and CD86,
resp.) receptors, present on the surfaces of APC. The inter-
action between these molecules promotes the differentiation
and activation of T effector cells, togetherwith the production
of associated cytokines, triggering the immune response [106,
107]. Naive T cells highly express CD28 molecule which
avidly interacts with B7 molecules present on APC. The
interaction between CD28L/B7 induces the secretion of IL-
2 and interferes with the tolerogenic property of immature
DC. This occurs primarily by decreasing the induction of
regulatory T cells and also by leveraging the differentiation
of effector T cells [63].
On the other hand, the cytotoxic T Lymphocyte Antigen-
4 (CTLA4) molecule, also known as CD152, acts as an
inhibitory receptor of the immune response; that is, it
blocks the binding site between CD28 and B7, providing a
negative signal to T lymphocytes, thus inhibiting the immune
response [148, 149]. Also, the inhibitory signals released by
the interaction between CTLA4 and B7 result in an increased
secretion of immunomodulatory cytokines, such as IL-10 and
TGF-𝛽, and hence the generation of Treg cells [108, 150, 151].
Suppression or anergy, induced by CTLA4, are associated
with Treg functions [152]. A recent research has shown that
CTLA4molecule can also be found on DC.The cross-linking
of CTLA4 can inhibit the maturation of DC, playing an
inhibitory role in immune response [153].
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IDO
CTLA4-Ig
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Figure 2: Mechanism of action of CTLA4-Ig on DC. CTLA4-Ig soluble molecule binds to B7 (CD80/CD86) molecules on DC. CTLA4
presents a higher affinity to B7 molecule and competes with CD28 for this ligation. This interaction induces downregulation of B7 gene
transcription and upregulation of IDO as well as secretion of sHLA-G. sHLA-G can stimulate Th2 and inhibit Th1 profile. DC: dendritic
cell; CTLA4-Ig: extracellular domain of human CTLA4 with a portion of the Fc region of IgG; IDO: indoleamine 2,3-dioxygenase; sHLA-G:
soluble HLA-G; Th: T helper; IL: interleukin; IFN: interferon; TNF: tumor necrosis factor.
Since CD80/CD86 molecules present a higher affinity
for CTLA4 rather than for CD28 molecule on the T cells,
the binding of CTLA4 and B7 family molecules makes it
possible to achieve tolerance to the allograft [152, 154]. It
has been demonstrated that CTLA4-deficient mice exhibit
severe autoimmune phenotype with early death 3 to 4 weeks
after birth, resulting from themassive destruction of multiple
organs, demonstrating the fundamental role of CTLA4 in the
regulation of peripheral self-reactive T cells [155].
Based on this knowledge and on the attempt of mod-
ulating the immune response in allografts, recombinant
molecules of CTLA4 linked to immunoglobulins (Ig) have
been developed (CTLA4-Ig).Thesemolecules, termed fusion
protein antagonist CTLA4-Ig, combine the extracellular
domain of human CTLA4 with a portion of the Fc region of
IgG. As represented in Figure 2, the CTLA4-Ig, initially tested
for the treatment of rheumatoid arthritis, has shown greater
affinity for B7, acting directly on APC and optimizing the
inhibition of the immune response [107, 108]. The inhibition
mechanism can also be related to the fact that CTLA4-Ig-
treated DC suppresses T cell proliferation through sHLA-G
secretion. Additionally, CTLA4-Ig induces IDO expression
in DC [88, 92, 156]. sHLA-G was associated with an increase
in the number of regulatory T cells and a shift of cytokine
towards Th2 [157].
In this context, Abatacept, a commercial CTLA4-Ig,
selectively modulates the immune response by binding with
high affinity to the B7 family present on APC. Thus, this
drug inhibits the activation of T cells by competing by the
binding site of CD28 receptors, preventing the secondary
signal from occurring [109, 110]. In human model, the T
cell hyporesponsiveness was also associated with a higher
expression of a negative regulator of proliferation, named
p27kip1 (cyclin-dependent kinase inhibitor 1B [CDKN1B])
[111]. Another recombinant molecule with an altered form,
Belatacept, has been approved for its use in transplants. This
molecule is known for having major affinity against CD86
[112–114]. A study with kidney-transplanted patients treated
with Belatacept demonstrates that transplanted patients who
received treatment with CTLA4-Ig had higher plasma levels
of sHLA-G. It can be hypostasized that the immunosuppres-
sive action of sHLA-G isoforms in transplants is associated
with the suppression of allogeneic T cells expansion and the
inhibition of the activation of both CD8+ T cells and NK
cells [88, 154]. In summary, the inhibitory signals carried by
the blockage of the CTLA4 molecule with CTLA4-Ig can be
related to the attenuation of stimulatory signal, decreasing the
cell proliferation, and cell cycle progression and alteration in
cytokine production of effector T cells.
As schematized in Figure 3, CTLA4 fused to the endo-
plasmic reticulum retention/retrieval signal sequence named
KDEL (CTLA4-KDEL) is a fusion protein that targets the
endoplasmic reticulum (ER). CTLA4-KDEL is confined to
ER and binds to CD80/86, preventing their passage to the
cell surface by interactionwith receptors. APC expressing this
construct retain CD80/CD86 molecules in the endoplasmic
reticulum and fail to express these costimulatory molecules
on their surface [158–160]. A recent study demonstrated the
applicability of modulating the signal transduction inmurine
DC with CTLA4-KDEL in order to inhibit immune response
in corneal transplantation. CTLA4-KDEL-expressing DC
adopted a tolerogenic phenotype and induced anergy in
alloreactive T cells, both in vitro and in vivo, resulting in a
long-term survival of corneal allografts [72]. CTLA4-Ig in
DC cultures showed the expected reduction in IFN-𝛾 and IL-
4 which may be associated with the upregulation of IDO in
DCs, not seen in CTLA4-KDEL-transfected cells [72, 115].
The interactions between CD40 and CD40L, expressed
on APC and T cells, respectively, are strictly related with
allograft immune response. As represented in Figure 4, it has
been shown that the blockage of the CD40-CD40L interac-
tion improves allograft survival by preventing the occurrence
of acute rejection [116, 124, 125, 161]. Therapy with anti-
CD40L (CD154) MAb prolonged the survival of the corneal
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Figure 3: Hypothetical mechanism of action of CTLA4-KDEL
fusion protein. Transport of proteins between the ER and Golgi
apparatus is mediated by two membrane coat complexes, COPI and
COPII. COPII mediates ER-to-Golgi transport and COPI medi-
ates retrograde transport. KDEL receptor undergoes retrograde
transport only after it binds its ligand [147]. On CTLA4-KDEL
transfected cells, the KDEL peptide retains/retrieves proteins to the
ER. CTLA4 fused to KDEL is confined to the ER where it binds
CD80/86, preventing the passage of these molecules to the cell
surface. CD80/CD86molecules seem to be removed by proteasome-
mediated degradation. GC: complex of Golgi; N: nucleus; ER:
endoplasmatic reticulum; CTLA4-KDEL: gene construct encoding
a modified CTLA4 molecule; COP: cytosolic protein coat complex.
allograft by increasing the frequency of spleen IL-10+CD4+ T
cells and decreasing IFN-𝛾+CD4+ T cells. Also, the Treg/Th1
cell ratio was increased in experimental model [162]. Since
therapieswith anti-CD40 or anti-CD40LMAbpresented sev-
eral thromboembolic complications in clinical applications,
further studies are ongoing to evaluate the combination of
these molecules [126, 130, 161]. Accordingly, the therapy of
CTLA4-Ig and a nondepleting CD40 monoclonal antibody,
named 3A8, is a promising combination [126], since prelim-
inary data showed an increased duration of graft acceptance
with this immunosuppressive treatment [126, 127].
Programmed death- (PD-) 1 ligand (PD-L1 or B7-H1)
and PD-L2 (B7-DC) are new B7 family members expressed
on APC. PD-1 and PD-1L/PD-L2 costimulatory signals play
important roles in T cell induced immune responses; PD-
L1 and PD-L2 deliver inhibitory signals that regulate T cell
activation and tolerance [136]. In a corneal allograft model,
PD-1 prolonged transplant survival by PD-L1 interaction
[137]. In this sense, dimeric PD-L1 immunoglobulin (Ig)
fusion protein (PD-L1.Ig) seems to be another combinatory
therapy in transplants as in corneal allograft, where PD-L1.Ig
showed significant suppression on T cell activation [137, 138,
163]. However, further studies will be required to determine
the therapeutic property of this molecule.
Additionally, T cell immunoglobulin domain and
mucin domain (TIM) family is a newly discovered group
of molecules that regulate immune cell function. TIM-
1 molecule is expressed on T cells and APC [139]. The
interaction between TIM-1 and TIM-4 promotes Th2
responses, and the blockage of this interaction can decrease
allergic responses [140, 141]. RMT1-10, an anti-TIM-1
monoclonal antibody, was effective in blocking TIM-1 and in
promoting corneal allograft survival in mice [141].
There are other coadjutant costimulatory blocking
molecules that are under evaluation. Anti-OX40-L MAb
therapy prevents memory T cell-mediated cardiac allograft
vasculopathy in mice, suggesting a potential therapy for
inhibition of OX40-OX40L signaling [128, 129, 142]. This
MAb seems to act by reducing the pool of effector T cells
responses, most part of these being CD8+ T cells [143].
Human leukocyte function antigen-3 (LFA-3) is an adhe-
sion and costimulation molecule, found on a variety of
APC, which interacts with ligand CD2 on T cells. LFA3-Ig
(Alefacept), a humanized chimeric fusion protein, comprises
an extracellular CD2-binding portion of the LFA3 linked to
the Fc portion of a human IgG1. LFA3-Ig promotes renal
allograft survival by depleting CD8+ effector memory T cells
and interfering with T cell activation [113, 144, 145]. Also, this
molecule can activate Fc gamma R(+) cells, such as NK cells,
to induce apoptosis of sensitive CD2(+) target cells [144, 146].
4.2. Other Modulatory Agents on Tolerogenic Dendritic Cell.
A new approach in the attempt of combining treatments with
autologous tolerogenic DC and anti-CD3 antibodies is under
development. This therapy was shown to be effective in mice
with pancreatic islet allografts by providing a reduction of
T cells infiltration. However, these protocols are still under
clinical development [164, 165].
Alternative methods for modulating tol-DC using tol-
erance-inducing agents such as dexamethasone (Dexa),
rapamycin (Rapa), and vitamin D3 (VitD3) are also under
evaluation [54]. Dexa-treated-DC triggered by lipopolysac-
charide (LPS) led to the suppression of proliferative response
of primed T cells, triggering the differentiation of various
populations of Tregs [166]. In another experimental study,
BALB/c mice that received a corneal transplantation were
treated with an analogue of resolvin D1 (RvD1). Resolvin D1
is a lipid mediator that plays an important role in resolu-
tion of acute inflammation. RvD1 modulated DC showed a
significant reduction inmaturation. Also, interferon-gamma-
secreting T cell frequency was decreased and alloimmune
sensitization was reduced after transplantation [167].
5. Concluding Remarks
Organ and tissue transplantation is still a last resource,
being only considered in cases such as total organ failure.
Thus, avoidance of rejection of transplanted organs is a key
task. Current allograft therapies can cause many side effects;
hence several alternative therapies, aiming the induction
of tolerance, mainly based on infusion of DC and Tregs,
have been proposed in the attempt of aiding this scenario.
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Figure 4: Anti-CD40L interaction and effects on T cells. Costimulatory molecule CD40L is primarily expressed on activated CD4+ T
lymphocytes. Anti-CD40L binds to the CD40L present on T cell and blocks its interaction with CD40 receptor present on APC. Therapy
with anti-CD40L (CD154) or anti-CD40 MAb, alone or combined with other molecules, downregulates T cell proliferation, Th1 cytokine
production, and antibody secretion. CD40L: CD40 ligand; APC: antigen-presenting cell.
Accordingly, immature DC expressing low levels of MHC
and costimulatory molecules has been considered among the
treatments due to its low capacity to activate T cells, thus
promoting a natural immunosuppression, which reduces the
need of using immunosuppressive drugs.
The modulation of DC with CTLA4-Ig has shown pos-
itive effects on suppressing the immune response. Although
many studies involving fusion proteins, and evenmonoclonal
antibodies, are in early stages, this is a very promising tool and
has great clinical potential in reducing transplant rejection.
Among the promising treatments, the effectiveness of using
CTLA4-Ig in immune modulation and in the induction of
tol-DC has been shown, even though the use of tolerogenic
cells for therapeutic purposes on transplantation is still not
widely available in clinical practice.
Essentially, the main challenge in these therapies is to
fixate the DC phenotype, since tol-DC can only be deter-
minate by its tolerogenic effect. Thus, the fine control of the
subtle balance between immunization and tolerance by DC is
necessary to allow the use of DC in clinical practice.
Despite being a very promising therapy, studies of adverse
effects should be extensive, since the use of biotechnology
in medical treatment, in the transplantation scenario in
particular, can be very risky if not thoroughly understood.
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